KOPRAN
|
The Current P/E Ratio of KOPRAN is 24.93.
Share Price | ₹306.6 | Nov 08,2024 |
Market Cap | ₹1,477.8 Cr | |
Earnings-TTM | ₹59.3 Cr | TTM-Consolidated Results |
Price/Earnings | 24.93x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,477.8 Cr] as on Nov 08,2024
(/) Earnings [ ₹59.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 24.93x ]
Thus, for KOPRAN , the investors are currently willing to pay 24.93 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 15.77x.
- KOPRAN 's operated at median p/e ratio of 19.55x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2020 of 5.22x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
KOPRAN | 59.28 | 24.93 | 1,477.8 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 39.03 | 434,604.0 |
CIPLA LTD | 4,485.22 | 28.66 | 128,549.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 19.78 | 106,956.0 |
ZYDUS LIFESCIENCES LTD | 4,181.90 | 23.31 | 97,468.9 |
DIVIS LABORATORIES LTD | 1,674.00 | 94.17 | 157,639.0 |
MANKIND PHARMA LTD | 2,124.86 | 50.13 | 106,527.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 60.01 | 108,130.0 |
LUPIN LTD | 2,651.94 | 36.20 | 95,997.1 |
AUROBINDO PHARMA LTD | 3,533.22 | 21.82 | 77,104.3 |
ABBOTT INDIA LTD | 1,284.66 | 47.26 | 60,713.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 19.78x |
Max industry PE | 94.17x |
Median industry PE | 36.20x |
Average industry PE | 40.48x |
You may also like the below Video Courses